402.70
-13.50
(-3.24%)
At close: January 10 at 3:40:02 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
3,672,657.00
3,334,625.00
3,490,553.00
3,981,625.00
3,713,492.00
Cost of Revenue
1,372,079.00
1,429,271.00
1,637,953.00
1,653,705.00
1,436,819.00
Gross Profit
2,300,578.00
1,905,354.00
1,852,600.00
2,327,920.00
2,276,673.00
Operating Expense
1,984,738.00
1,811,244.00
1,862,831.00
1,936,227.00
1,608,556.00
Operating Income
315,840.00
94,110.00
-10,231.00
391,693.00
668,117.00
Net Non Operating Interest Income Expense
-125,033.00
-138,523.00
-193,370.00
-166,616.00
-154,574.00
Pretax Income
228,706.00
-98,730.00
-513,052.00
269,431.00
516,306.00
Tax Provision
148,358.00
141,357.00
18,265.00
118,825.00
91,002.00
Net Income Common Stockholders
84,684.00
-230,598.00
-510,752.00
154,471.00
455,066.00
Diluted NI Available to Com Stockholders
84,684.00
-230,598.00
-510,752.00
154,471.00
455,066.00
Basic EPS
2.92
-7.99
-17.70
5.35
15.77
Diluted EPS
2.92
-7.99
-17.70
5.33
15.69
Basic Average Shares
28,912.35
28,874.11
28,857.30
28,847.32
28,847.32
Diluted Average Shares
29,224.38
29,186.15
29,186.15
29,002.33
29,004.79
Rent Expense Supplemental
--
37,084.00
19,374.00
10,786.00
9,561.00
Total Expenses
3,356,817.00
3,240,515.00
3,500,784.00
3,589,932.00
3,045,375.00
Net Income from Continuing & Discontinued Operation
84,684.00
-230,598.00
-510,752.00
154,471.00
455,066.00
Normalized Income
86,774.20
-176,523.00
-272,932.60
144,428.80
473,888.55
Interest Income
--
35,731.00
20,354.00
13,163.00
35,461.00
Interest Expense
145,939.00
159,429.00
189,919.00
162,686.00
156,694.00
Net Interest Income
-125,033.00
-138,523.00
-193,370.00
-166,616.00
-154,574.00
EBIT
374,645.00
60,699.00
-323,133.00
432,117.00
673,000.00
EBITDA
625,773.00
307,892.00
-40,658.00
687,733.00
876,084.00
Reconciled Cost of Revenue
1,372,079.00
1,429,271.00
1,637,953.00
1,653,705.00
1,436,819.00
Reconciled Depreciation
251,127.00
247,192.00
282,475.00
255,616.00
203,084.00
Net Income from Continuing Operation Net Minority Interest
84,684.00
-230,598.00
-510,752.00
154,471.00
455,066.00
Total Unusual Items Excluding Goodwill
-2,986.00
-77,250.00
-339,742.00
14,346.00
-22,850.00
Total Unusual Items
-2,986.00
-77,250.00
-339,742.00
14,346.00
-22,850.00
Normalized EBITDA
628,759.00
385,142.00
299,084.00
673,387.00
898,934.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-895.80
-23,175.00
-101,922.60
4,303.80
-4,027.45
3/31/2021 - 12/30/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NOVARTIND.BO Novartis India Limited
879.60
-3.76%
NECLIFE.NS Nectar Lifesciences Limited
38.25
+0.84%
ALBERTDAVD.NS Albert David Limited
1,220.20
-6.24%
ASTRAZEN.NS AstraZeneca Pharma India Limited
6,907.35
-2.56%
BAJAJHCARE.NS Bajaj HealthCare Limited
536.65
-1.64%
SPARC.NS Sun Pharma Advanced Research Company Limited
183.52
-3.13%
IOLCP.NS IOL Chemicals and Pharmaceuticals Limited
409.15
-3.31%